Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.
“The simplification of single-cell, multiple edit genome engineering to an automated, benchtop process will democratize gene writing in the same way that Illumina’s efforts did for gene reading 10 years ago. It will enable many more scientists to rapidly conduct genomic research and develop new products across multiple applications in healthcare, agriculture, and industrial biotechnology,” said Bryan Roberts, Partner at Venrock. “Muse bio can fulfill this promise.”
“We are excited to be funded by this high-quality group of investors with a proven track record of success. They recognize the value of Muse bio’s technology, which enables scientists to make multiple, clearly defined genomic modifications at any site within a cell’s genome in a high-throughput and cost-effective manner,” said Kevin Ness, CEO of Muse bio. “The proceeds from this financing will allow us to accelerate our timelines to bring ForgeCraft™ to scientists worldwide.”
About Muse bio
Muse bio is enabling a new era of genome engineering that will transform our understanding of biology. Muse bio delivers power to researchers and production scientists in the field of genome engineering and synthetic biology through the combination of a powerful computer aided forward design software package, a proprietary benchtop biofoundry, and custom reagents. Its next-generation, CRISPR-based ForgeCraft technology dramatically accelerates genome engineering.